Christopher R Porter
Overview
Explore the profile of Christopher R Porter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Pham K, Johnston R, Jeldres C, Nichols C, Porter C
Urol Pract
. 2023 Aug;
1(3):151-155.
PMID: 37537819
Introduction: Clinical stage I seminoma can be managed with surveillance, chemotherapy or radiotherapy with similar survival rates. However, costs and side effects vary among these treatment modalities. We created a...
3.
Pham K, Johnston R, Jeldres C, Lewinshtein D, Porter C
Urol Pract
. 2023 Aug;
2(2):85-89.
PMID: 37537814
Introduction: The impact of transrectal ultrasound guided prostate needle biopsy on erectile dysfunction remains uncertain. We examined whether transrectal ultrasound guided prostate needle biopsy contributes to the development or worsening...
4.
5.
Stroup S, Robertson A, Onofaro K, Santomauro M, Rocco N, Kuo H, et al.
Cancer Med
. 2022 May;
11(24):4756-4766.
PMID: 35616266
Background: Previous research exploring the role of race on prostate cancer (PCa) outcomes has demonstrated greater rates of disease progression and poorer overall survival for African American (AA) compared to...
6.
Donahue R, Stamm A, Daily A, Kozlowski P, Porter C, Govier F, et al.
Urology
. 2022 Mar;
166:202-208.
PMID: 35314185
Objective: To assess whether a multimodal opioid-limiting protocol and patient education intervention can reduce postoperative opioid use following transurethral resection of the prostate. Methods: This prospective, non-blinded, single-institution, randomized controlled...
7.
Frankel J, Caumont F, DeBerg H, Flores J, Porter C
Urol Oncol
. 2021 Feb;
39(4):240.e1-240.e8.
PMID: 33602622
Purpose: Surveillance is now the preferred treatment strategy for patients with stage 1A/1B seminoma as reflected by the National Comprehensive Cancer Network guidelines. In this study, we aimed to describe...
8.
Caumont F, Conti G, Hurwitz L, Kuo C, Levie K, Badiozamani K, et al.
Urol Oncol
. 2020 Mar;
38(10):794.e1-794.e9.
PMID: 32139288
Introduction: Combined radiotherapy and hormonal treatment are recommended for intermediate- and high-risk prostate cancer (CaP). This study compared the long-term effects on health-related quality of life (HRQoL) of intermediate- and...
9.
Trabulsi E, Rumble R, Jadvar H, Hope T, Pomper M, Turkbey B, et al.
J Clin Oncol
. 2020 Jan;
38(17):1963-1996.
PMID: 31940221
Purpose: Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this...
10.
Alsinnawi M, Cullen J, Hurwitz L, Levie K, Burns J, Rosner I, et al.
Can J Urol
. 2019 Aug;
26(4):9809-9820.
PMID: 31469635
Introduction: To assess the impact of primary and secondary therapies for high- and intermediate-risk prostate cancer on health-related quality of life (HRQoL). Materials And Methods: A prospective study was initiated...